Robert J Motzer

Robert J Motzer

UNVERIFIED PROFILE

Are you Robert J Motzer?   Register this Author

Register author
Robert J Motzer

Robert J Motzer

Publications by authors named "Robert J Motzer"

Are you Robert J Motzer?   Register this Author

100Publications

3333Reads

31Profile Views

Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors.

J Clin Oncol 2019 Sep 24;37(26):2329-2337. Epub 2019 Jun 24.

Memorial Sloan Kettering Cancer Center, New York, NY and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01608DOI Listing
September 2019

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Eur Urol Oncol 2019 Sep 1;2(5):505-514. Epub 2019 Aug 1.

Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.06.022DOI Listing
September 2019

The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy.

Acta Oncol 2019 Aug 29:1-8. Epub 2019 Aug 29.

National Health and Medical Research Council Clinical Trials Centre, The University of Sydney , Sydney , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1656342DOI Listing
August 2019

The current role for adjuvant and neoadjuvant therapy in renal cell cancer.

Curr Opin Urol 2019 Jul 24. Epub 2019 Jul 24.

Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000666DOI Listing
July 2019

Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply.

N Engl J Med 2019 06;380(26):2581-2582

Pfizer, Groton, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1905518DOI Listing
June 2019

Towards individualized therapy for metastatic renal cell carcinoma.

Nat Rev Clin Oncol 2019 Apr 16. Epub 2019 Apr 16.

Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0209-1DOI Listing
April 2019

Author Correction: Towards individualized therapy for metastatic renal cell carcinoma.

Nat Rev Clin Oncol 2019 Apr 25. Epub 2019 Apr 25.

Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-019-0214-4DOI Listing
April 2019

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 03 16;380(12):1103-1115. Epub 2019 Feb 16.

From Memorial Sloan Kettering Cancer Center (R.J.M.) and Pfizer (S.H.), New York; Private Medical Institution Euromedservice (K.P.) and Nonstate Health Institution Road Clinical Hospital-Russian Railways (A.V.), St. Petersburg, and the Moscow Scientific Research Oncology Institute, Moscow (B.A.) - all in Russia; the Netherlands Cancer Institute, Amsterdam (J.H.); the Cleveland Clinic, Cleveland (B.R.); Institut Gustave Roussy, Villejuif (L.A.), and Centre Léon Bérard, University of Lyon, Lyon (S.N.) - both in France; the University of Texas M.D. Anderson Cancer Center, Houston (M.T.C.); University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow (B.V.), and Royal Marsden NHS Foundation Trust, London (J.L.) - both in the United Kingdom; British Columbia Cancer Agency, Vancouver (C.K.), and Lady Davis Institute and Jewish General Hospital, McGill University, Montreal (W.H.M.) - both in Canada; Osaka University Hospital, Osaka, Japan (M.U.); University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea (J.L.L.); Macquarie University, Sydney (H.G.); Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna (M.S.); Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.); Department of Urology, University of Tübingen, Tübingen, Germany (J.B.); Pfizer, Cambridge (J.W., A.C.), and the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and Brigham and Women's Hospital, Boston (T.K.C.) - both in Massachusetts; Pfizer (M.M., A.P.) and Pfizer Italia (C.F.), Milan; Pfizer, San Diego, CA (P.B.R.); and Pfizer, Groton, CT (B.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716603PMC
March 2019

Combination therapy for advanced and metastatic kidney cancer.

Nat Rev Urol 2019 Feb;16(2):77-78

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41585-018-0133-7
Publisher Site
http://dx.doi.org/10.1038/s41585-018-0133-7DOI Listing
February 2019

Cytoreductive Nephrectomy - Patient Selection Is Key.

N Engl J Med 2018 08 3;379(5):481-482. Epub 2018 Jun 3.

From the Genitourinary Oncology Service, Department of Medicine (R.J.M.), and the Urology Service, Department of Surgery (P.R.), Memorial Sloan Kettering Cancer Center, and the Departments of Medicine (R.J.M.) and Urology (P.R.), Weill Cornell Medical College - both in New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMe1806331DOI Listing
August 2018

Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma.

N Engl J Med 2018 07;379(1):92-93

Bristol-Myers Squibb, Princeton, NJ

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1805988DOI Listing
July 2018

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med 2018 Apr 21;378(14):1277-1290. Epub 2018 Mar 21.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile; Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France; Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London; Aarhus University Hospital, Aarhus, Denmark (F.D.); Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.); British Columbia Cancer Agency, Vancouver, Canada (C.K.K.); Westmead Hospital and Macquarie University, Sydney (H.G.); Jena University Hospital, Jena, Germany (M.-O.G.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.); Niigata University, Niigata, Japan (Y.T.); Hospital Universitario 12 de Octubre, Madrid (D.C.); Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.); and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1712126
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1712126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972549PMC
April 2018

Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.

J Clin Oncol 2018 03 8;36(8):765-772. Epub 2018 Jan 8.

Bernard Escudier, Institut Gustave Roussy, Villejuif; Stephane Oudard, Hôpital Européen Georges Pompidou, Paris; Frederic Rolland, Centre René Gauducheau Centre de Lutte Contre Le Cancer Nantes, Saint-Herblain, France; Thomas Powles, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; Thomas Olencki, Ohio State University, Columbus, OH; Osvaldo Arén Frontera, Centro Internacional de Estudios Clinicos, Santiago, Chile; Piotr Tomczak, Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego, Poznań, Poland; Daniel Castellano, Hospital Universitario 12 de Octubre, Madrid, Spain; Leonard J Appleman, University of Pittsburgh Medical Center, Pittsburgh, PA; Harry Drabkin, Medical University of South Carolina, Charleston, SC; Daniel Vaena, University of Iowa Hospitals and Clinics, Iowa City, IA; Steven Milwee, Jillian Youkstetter, and Julie C. Lougheed, Exelixis, Inc., San Francisco, CA; Sergio Bracarda, Ospedale San Donato, Istituto Toscano Tumori (ITT), Arezzo, Italy; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7352DOI Listing
March 2018

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

J Clin Oncol 2018 03 29;36(8):757-764. Epub 2018 Jan 29.

David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Bernard Escudier, Institut Gustave Roussy, Villejuif; Florence Marteau, Ipsen Pharma, Boulogne-Billancourt; Paul Williams, Mapi Group, Lyon, France; Nizar M. Tannir, University of Texas MD Anderson Cancer Center Hospital, Houston; Hans J. Hammers, University of Texas Southwestern Medical Center; Thomas E. Hutson, Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX; Thomas Powles, Queen Mary University of London, London, United Kingdom; Frede Donskov, Aarhus University Hospital, Aarhus, Denmark; Katriina Peltola, Helsinki University Hospital Cancer Center, Helsinki, Finland; Manuela Schmidinger, Medical University of Vienna, Vienna, Austria; Daniel Y.C. Heng, University of Calgary, Calgary, Alberta, Canada; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; Jae Lyun Lee, University of Ulsan College of Medicine, Seoul, South Korea; Bruce J. Roth, Washington University in St Louis, St Louis, MO; John Baer, Milan Mangeshkar, and Christian Scheffold, Exelixis, South San Francisco; Sumanta Pal, City of Hope National Medical Center, Duarte, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2170DOI Listing
March 2018

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

J Clin Oncol 2017 Dec 13;35(35):3916-3923. Epub 2017 Sep 13.

Robert J. Motzer and Paul Russo, Memorial Sloan Kettering Cancer Center, New York, NY; Naomi B. Haas, University of Pennsylvania, Philadelphia, PA; Frede Donskov, Aarhus University Hospital, Aarhus, Denmark; Marine Gross-Goupil, Bordeaux University Hospital, Bordeaux, France; Sergei Varlamov, Altai Regional Cancer Center, Barnaul; Evgeny Kopyltsov, State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia; Jae Lyun Lee, University of Ulsan College of Medicine; Ho Yeong Lim, Sungkyunkwan University, Seoul, Republic of Korea; Bohuslav Melichar, Palacky University Medical School and Teaching Hospital, Olomouc; Milada Zemanova, Charles University and General University Hospital, Prague, Czech Republic; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; Lori A. Wood, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; M. Neil Reaume, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Arnulf Stenzl, University Hospital Tübingen, Tübingen; Christian Doehn, University of Lübeck Medical School and Urologikum Lübeck, Lübeck, Germany; Simon Chowdhury, Guy's and St Thomas' National Health Service Foundation/St Thomas' Hospital, London; Ray McDermott, Tallaght University Hospital and Cancer Trials Ireland, Dublin; Agnieszka Michael, University of Surrey, Guildford, United Kingdom; Weichao Bao, Marlene J. Carrasco-Alfonso, and Maurizio Voi, Novartis Oncology, East Hanover, NJ; Paola Aimone, Novartis Pharma AG, Basel, Switzerland; and Cora N. Sternberg, San Camillo Forlanini Hospital, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.5324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018511PMC
December 2017

Optimizing Treatment Approaches in Advanced Renal Cancer.

Oncology (Williston Park) 2017 12;31(12):919-26, 928-30

View Article

Download full-text PDF

Source
December 2017

Perioperative Management of Localized Kidney Cancer: Watching and Waiting.

JAMA Oncol 2017 07;3(7):895-896

Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.4409DOI Listing
July 2017

Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.

J Urol 2017 02 5;197(2):391-397. Epub 2016 Oct 5.

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2016.09.113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241176PMC
February 2017

Immune Checkpoint Therapy in Renal Cell Carcinoma.

Cancer J 2016 Mar-Apr;22(2):92-5

From the Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000177DOI Listing
January 2017

Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.

Oncologist 2017 01 2;22(1):41-52. Epub 2016 Nov 2.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2016-0197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313263PMC
January 2017

Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancer.

Nat Rev Nephrol 2017 01;13(2):69-70

Memorial Sloan-Kettering Cancer, Center Solid Tumor Oncology Division, 1275 York Avenue, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneph.2016.194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573185PMC
January 2017

Systemic Therapy for Metastatic Renal-Cell Carcinoma.

N Engl J Med 2017 01;376(4):354-366

From the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston (T.K.C.); and the Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMra1601333DOI Listing
January 2017

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

N Engl J Med 2016 12 9;375(23):2246-2254. Epub 2016 Oct 9.

From the Department of Medical Oncology, Bordeaux University Hospital, Bordeaux (A.R.), Department of Medical Oncology, Institut Gustave Roussy, Villejuif (B.E.), Medical Oncology, Centre Eugene Marquis, Rennes (B.L.), and Department of Urology, Bicêtre Hospital, Paris-Saclay University, Le Kremlin Bicêtre (J.-J.P.) - all in France; Department of Medicine, Memorial Sloan Kettering Cancer Center (R.J.M.), and Pfizer (K.R.) - both in New York; Department of Clinical and Experimental Medicine, University of Surrey, Surrey, United Kingdom (H.S.P.); Division of Medical Oncology, Duke Cancer Institute, Durham, NC (D.J.G.); Department of Urology, Ronald Reagan UCLA Medical Center, Los Angeles (A.J.P.), and Pfizer, La Jolla (X.L., J.-F.M.) - both in California; Spire Roding Hospital, London (A.P.); Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Department of Oncology, Aarhus University Hospital, Aarhus, Denmark (F.D.); Department of Urology, Charité Universitätsmedizin Berlin, Berlin (A.M.), and Department of Urology, University Hospital of Munich, Munich (M.S.) - both in Germany; Divisions of Oncology and Urology, Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Naples, Italy (G.C.); Klinika Onkologii Oddzial Chemioterapii, Poznan, Poland (P.T.); Department of Urology, Slovak Medical University, Bratislava, Slovakia (J.B.); and Pfizer, Milan (P.G., M.L.), and Collegeville, PA (M.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1611406DOI Listing
December 2016

Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.

J Clin Oncol 2016 11;34(32):3846-3853

Martin H. Voss, Ying-Bei Chen, Kaitlin M. Woo, Joshua L. Chaim, Devyn T. Coskey, Almedina Redzematovic, Patricia Wang, William Lee, S. Duygu Selcuklu, Chung-Han Lee, Michael F. Berger, Satish K. Tickoo, Victor E. Reuter, Sujata Pati, James J. Hsieh, Robert J. Motzer, and Darren R. Feldman, Memorial Sloan Kettering Cancer Center; and Ana M. Molina, Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.9084DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791841PMC
November 2016

Perspective: What next for treatment?

Authors:
Robert J Motzer

Nature 2016 09;537(7620):S111

Memorial Sloan Kettering Cancer Center in New York City.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/537S111aDOI Listing
September 2016

Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.

J Clin Oncol 2016 07 16;34(21):2478-83. Epub 2016 May 16.

Darren R. Feldman, Kristina Lim, Sujata Patil, Kaitlin M. Woo, Maryann Carousso, Amanda Hughes, Joel Sheinfeld, Manjit Bains, Dean F. Bajorin, George J. Bosl, and Robert J. Motzer, Memorial Sloan Kettering Cancer Center; Darren R. Feldman, Dean F. Bajorin, George J. Bosl, and Robert J. Motzer, Weill Medical College of Cornell University, New York, NY; and James Hu, Tanya B. Dorff, Siamak Daneshmand, Charlene Ketchens, and David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7899DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320896PMC
July 2016

Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.

Nat Rev Urol 2016 07 21;13(7):420-31. Epub 2016 Jun 21.

Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrurol.2016.103
Publisher Site
http://dx.doi.org/10.1038/nrurol.2016.103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532875PMC
July 2016

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.

J Clin Oncol 2016 05 7;34(14):1660-8. Epub 2016 Mar 7.

Thomas Powles, Queen Mary University of London, London; Christy Ralph, University of Leeds, Leeds; Janet E. Brown, University of Sheffield, Sheffield; Robert E. Hawkins, University of Manchester, Manchester, United Kingdom; Mark R. Lackner, Wei Lin, Bridget O'Keeffe, Yulei Wang, Shan Lu, Jill M. Spoerke, Ling Yuh Huw, Michelle Byrtek, Rui Zhu, and Joseph A. Ware, Genentech, South San Francisco, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Bernard Escudier, Institut Gustave Roussy, Villejuif; Alain Ravaud, Hospital Saint Andre, Bordeaux; Stéphane Oudard, University Paris Descartes, Paris, France; Daniel Castellano, University Hospital 12 de Octubre, Madrid, Spain; and Michael D. Staehler, University Hospital Munich-Grosshadern, Marchioninistrasse, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.8808DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569691PMC
May 2016

Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma.

Cancer 2016 Apr 27;122(7):1108-15. Epub 2016 Jan 27.

Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29888DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4996632PMC
April 2016

Treatment of Advanced Renal-Cell Carcinoma.

N Engl J Med 2016 03;374(9):889-90

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1515613DOI Listing
March 2016

Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma.

Urol Clin North Am 2016 Feb 31;43(1):95-104. Epub 2015 Oct 31.

Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 353 East 68th Street, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ucl.2015.08.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4864362PMC
February 2016

Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma.

Lancet Oncol 2016 Jan 23;17(1):e4-5. Epub 2015 Dec 23.

Royal Marsden Hospital NHS Foundation Trust, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00543-4DOI Listing
January 2016

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.

Br J Cancer 2015 Dec 22;113(11):1571-80. Epub 2015 Oct 22.

Cleveland Clinic Taussig Cancer Institute, Glickman Urological Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2015.368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705883PMC
December 2015

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1803-13. Epub 2015 Sep 25.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; Institut Gustave Roussy, Villejuif (B.E.), and Bordeaux University Hospital, Hôpital Saint André, Bordeaux (A.R.) - both in France; Beth Israel Deaconess Medical Center (D.F.M.) and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.) - all in Boston; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.); Stanford Cancer Institute, Stanford, CA (S.S.); University of Washington and Fred Hutchinson Cancer Research Center, Seattle (S.S.T.); Vanderbilt University Medical Center, Nashville (J.A.S.); Fondazione Istituto Nazionale Tumori, Milan (G.P.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hospital Universitario 12 De Octubre, Madrid (D.C.); Westmead Hospital and Macquarie University, Sydney (H.G.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Helsinki University Central Hospital and University of Helsinki, Helsinki (P.B.); South West Wales Cancer Institute and Swansea University College of Medicine, Swansea (J.W.), and Royal Marsden Hospital, London (J.L.) - both in the United Kingdom; University Hospital Essen of University of Duisburg-Essen, Germany (T.C.G.); Chiba Cancer Center, Chiba (T.U.), and Niigata University, Niigata (Y.T.) - both in Japan; Hospital Sao Jose, Beneficencia Portuguesa de São Paulo, São Paulo (F.A.S.); British Columbia Cancer Agency, Vancouver, BC, Canada (C.K.); Bristol-Myers Squibb, Lawrenceville (J.S.S., I.M.W.) and Hopewell (L.-A.X.) - both in New Jersey; and M.D. Anderson Cancer Center, University of Texas, Houston (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510665DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719487PMC
November 2015

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1814-23. Epub 2015 Sep 25.

From the Dana-Farber Cancer Institute, Boston (T.K.C., P.W.K.); Institut Gustave Roussy, Villejuif, France (B.E.); Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); Icon Cancer Care, South Brisbane, QLD, Australia (P.N.M.); Cleveland Clinic, Cleveland (B.I.R.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (H.H.); Texas Oncology-Charles A. Sammons Cancer Center, Baylor University, Dallas (T.E.H.); University of Ulsan College of Medicine (J.-L.L.) and Seoul National University Hospital (B.K.) - both in Seoul, South Korea; Helsinki University Central Hospital Cancer Center, Helsinki (K.P.); Washington University in St. Louis, St. Louis (B.J.R.); Sunnybrook Odette Cancer Centre, Toronto (G.A.B.), and Tom Baker Cancer Centre, Calgary, AB (D.Y.C.H.) - both in Canada; National Institute of Oncology, Budapest, Hungary (L.G.); Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.); Medical University of Vienna, Vienna (M.S.); Exelixis, South San Francisco, CA (A.B-H., C.H., C.S., G.M.S.); University of Texas M.D. Anderson Cancer Center, Houston (N.M.T.); and the Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024539PMC
November 2015